About Us

Charting New Territory, for Patients.

At CAMP4, we are pioneering a novel approach to design ASO therapeutics. Propriety insights from our RAP Platform® enable us to rapidly discover and develop ASO therapeutic candidates that upregulate gene expression, enabling the potential to address over a thousand diseases by restoring healthy protein levels.

About Us

We are pushing the boundaries of what is thought to be possible.

CAMP4 is the final camp before a climber’s final ascent to the summit of Mt. Everest. Additionally, CAMP4 is a sacred climbing haven in Yosemite where the greatest climbers gather to challenge themselves to attempt what was once thought to be impossible. Reaching CAMP4 is the culmination of months of pre-climb preparation, and weeks of perseverance, endurance and ingenuity. The risks to reach the summit or set new records, while significant, are outweighed by the promise of the ultimate reward. Like elite climbers, we at CAMP4 believe there is now an opportunity to conquer many diseases without treatments.

Our Leadership

Josh Mandel-Brehm

President & Chief Executive Officer

Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics.

Mr. Mandel-Brehm was previously an entrepreneur partner with Polaris Partners and held key business development and operations leadership roles at leading biotech companies. He served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions. Prior to Biogen, Mr. Mandel-Brehm was at Genzyme as part of the business development group for the company’s rare disease business unit. He is currently a board Director at Vico Therapeutics, a company he co-founded, and ProMIS Neuroscience.

Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Kelly Gold

Chief Financial Officer

Ms. Gold is the Chief Financial Officer at CAMP4 Therapeutics. She is responsible for guiding and executing the company’s strategy for establishing innovative strategic and technology-based partnerships that allow CAMP4 to realize the full value of the regRNA targeting approach. In addition, Ms. Gold leads all corporate finance and accounting, investor relations and strategic financial planning activities at CAMP4.

Ms. Gold joined CAMP4 in 2017 and has held roles of increasing responsibility leading the Business Development and Finance functions, most recently as Chief Business Officer and SVP, Finance. Prior to joining CAMP4, Ms. Gold held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization. Prior to Biogen, Ms. Gold worked in the Healthcare and Latin American Investment Banking groups at Deutsche Bank. Ms. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities.

Ms. Gold holds Bachelor’s degrees in Biochemistry and Mechanical Engineering from Queen’s University in Ontario, as well as an MBA from the MIT Sloan School of Management.

Yuri Maricich, MD

Chief Medical Officer

Yuri Maricich, MD, serves as Chief Medical Officer at CAMP4.

Dr. Maricich is a licensed physician-scientist, clinical/therapeutic developer, investor, and strategist. His background includes clinical practice as an internal medicine physician and leading teams developing therapeutics at companies such as Xdynia (acq Cavion), Cavion (acq Jazz Pharmaceuticals), Corixa (acq GlaxoSmithKline), Pear Therapeutics (public, 3 FDA authorized products including Somryst – Prix Galien best product). He is a Venture Partner & Advisor at Angelini Ventures.

Dr. Maricich has experience developing therapeutics across the entire product life cycle from discovery through approval/authorization, as well as post-market studies. He has worked across therapeutic modalities and disease areas, as well as in medical devices, digital health, and healthcare delivery.

Dr. Maricich earned a BS in Pre-Professional Studies from the University of Notre Dame, an MD from the University of Washington, and an MBA from Harvard University.

Dan Tardiff, PhD

Chief Scientific Officer

Dan Tardiff, PhD, is Chief Scientific Officer of CAMP4 where he oversees Platform and Discovery Teams to expand the scope of CAMP4’s discovery platform and advance the pipeline towards the clinic.

Prior to joining CAMP4, Dr. Tardiff led drug discovery projects and teams in both small biotech and large pharma across multiple drug modalities. Dr. Tardiff most recently led a team in the Rare Disease Research Unit at Pfizer exploring genetic medicines for rare neurological disorders. Prior to Pfizer, Dr. Tardiff was a scientific co-founder of Yumanity Therapeutics, where he helped build a platform to discover novel therapeutics for the treatment of neurodegenerative diseases. At Yumanity, he led teams from screening through translational research to discover new therapeutic targets and drug candidates, including a clinical-stage small molecule targeting stearoyl-CoA desaturase for the potential treatment of Parkinson’s disease.

Dr. Tardiff earned his BS in Biochemistry from Stonehill College and his PhD from Brandeis University. He completed his post-doctoral training at the Whitehead Institute for Biomedical Research with Dr. Susan Lindquist.

Michelle Gates

Chief People Officer

Michelle Gates is the Chief People Officer at CAMP4 Therapeutics, where she leads the company’s people strategy and oversees all aspects of Human Resources. She plays a key role in shaping CAMP4’s culture and supporting its rapid growth by aligning talent initiatives with the company’s mission and vision.

Ms. Gates brings extensive global experience and transformation leadership from her 16-year tenure at Akamai Technologies. As Vice President of Human Resources, she guided the company through significant international expansion, multiple acquisitions, and the evolution of its HR function. She led enterprise-wide initiatives, built centers of excellence, and scaled high-performing teams across regions. Her work was instrumental in developing Akamai’s enterprise security strategy and building global capabilities. Earlier in her career, Ms. Gates held HR leadership roles at British Telecom and Teradyne. She is passionate about building inclusive, collaborative teams and driving organizational excellence.

Ms. Gates holds a Bachelor of Arts in English and Spanish from Providence College and has completed executive education coursework at the Wharton School.

Caleb Moore

Chief Business Operations Officer

Caleb Moore is Chief Business Operations Officer at CAMP4 Therapeutics. He is responsible for guiding CAMP4’s disease selection and program strategy based on biological rationale and downstream development and commercial considerations. Mr. Moore leads CAMP4’s program leadership, alliance management, and portfolio strategy functions. He also oversees key operational activities.

Prior to joining CAMP4, Mr. Moore was Senior Director of Corporate Development at Acceleron Pharma, where he helped translate the company’s expertise in TGFβ biology into a focused therapeutic area strategy. He was instrumental in establishing Pulmonary as a pillar of Acceleron’s strategy based on the disease-modifying potential of its lead program in pulmonary arterial hypertension (PAH). Prior to Acceleron, Mr. Moore worked in Global New Product Planning at Cubist Pharmaceuticals, defining early commercial strategy for internal programs and external opportunities. He also held positions in Business Development & Strategy at Genzyme, steering multiple transactions that contributed to the growth of the rare disease and cardio-metabolic/renal businesses. Mr. Moore began his life sciences career at a boutique consulting and market research firm.

Mr. Moore earned a BA in Genetics, Cell & Developmental Biology from Dartmouth College and holds an MBA from the Tuck School of Business at Dartmouth.

Satya Kuchimanchi, PhD

Senior Vice President, Technical Operations

Satya Kuchimanchi, PhD, is Senior Vice President, Technical Operations and Chemistry, Manufacturing and Controls (CMC). He is responsible for overseeing manufacturing, quality assurance, and supply chain.

Prior to joining CAMP4, Dr. Kuchimanchi was Vice President, CMC at Triplet Therapeutics, where he led CMC and manufacturing of oligonucleotide therapeutics to treat neurodegenerative diseases. Previously, he held multiple roles at Alnylam over a period of 12 years, most recently as the Director of Process Development where he was responsible for drug substance process characterization and process control strategy, authored CMC sections for global regulatory filings and contributed to regulatory approval for four approved siRNA therapeutics.

Dr. Kuchimanchi received his PhD in Organic Chemistry from Osmania University, Hyderabad, India and held post-doctoral fellowships at the University of Montpellier, France and Vanderbilt University.

Alla Sigova, PhD

Senior Vice President, Platform

Alla Sigova, PhD, is Senior Vice President of Platform at CAMP4, where she leads the experimental and computational teams driving the development and implementation of the company’s core technology. In this role, she also oversees the execution of CAMP’s innovative strategic and technology-based partnerships.

Dr. Sigova originally joined CAMP4 in 2016 as the founding scientist and key architect of the core gene control mapping technology that underpins the company’s Platform today. Prior to re-joining CAMP4, Dr. Sigova led a multifunctional team at Laronde Therapeutics (currently Sail Biomedicines) focusing on advancing translatable RNA therapeutics towards clinical development.

Dr. Sigova earned her PhD in Biomedical Sciences from the UMass Medical School under the mentorship of Phillip Zamore and conducted her post-doctoral training in CAMP4 co-founder Rick Young’s laboratory at the Whitehead Institute for Biomedical Research. She is a co-author of multiple seminal publications in the field of gene regulation.

Douglas E. Williams, PhD

Chairman of the Board, Draig Therapeutics and Climb Bio; Board Member, eGenesis, Ormoni and Mosaica Medicines

Doug E. Williams, PhD, is a veteran of the biopharma industry with over 30 years of experience in R&D and contributions to the development of several innovative drug products, including LEUKINE®, ENBREL®, ADCETRIS®, TECFIDERA®, APROLIX®, ELOCTATE®, and SPINRAZA®. Dr. Williams was most recently President of R&D at Sana Biotechnology, a cell therapy company. He was the Founding President, CEO and member of the Board of Directors of Codiak BioSciences from 2015 to 2023. He was previously Biogen’s Executive Vice President, Research and Development, serving in this role from 2011 to 2015. Prior to Biogen, Dr. Williams was CEO and a member of the Board of Directors at ZymoGenetics, which was acquired for $985M by Bristol Myers Squibb during his tenure. Earlier in his career, Dr. Williams held a variety of leadership positions within biotech, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a member of the Board of Directors. He has served on the Board of Directors and Advisory Boards of more than two dozen biotechnology companies and is currently Chairman of the Boards of Draig Therapeutics and Climb Bio, and a member of the Boards of eGenesis, Ormoni and Mosaica Medicines.

Dr. Williams earned his PhD from The State University at Buffalo Roswell Park Division and completed his post-doctoral studies at Indiana University School of Medicine.

Steve Holtzman

Executive Chair of the Board, Qihan Biotech and Manifold Bio

Steve Holtzman is currently the Executive Chair of the Board of Directors of Qihan Biotech, the Executive Chair of the Board of Directors of Manifold Bio, a member of the Board of Directors of Molecular Partners, a Strategic Advisor to Digital Bio, a Strategic Business Advisor to Amplify Bio, and a strategic business advisor to Babylon Biosciences. Previously he was the founding CEO and member of the Board of Directors of Decibel Therapeutics, Executive Vice President of Corporate Development of Biogen, co-founder, CEO, and chair of the board of directors of Infinity Pharmaceuticals, Chief Business Officer of Millennium Pharmaceuticals, and co-founder, Executive Vice President, and member of the board of directors of DNX Corporation. Mr. Holtzman is a member of the board of trustees of the Berklee College of Music, and a senior fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School. He was appointed by President Clinton to the National Bioethics Advisory Commission, and served as a member and vice chair of the board of trustees of the Hastings Center for Ethics and the Life Sciences. Mr. Holtzman obtained his undergraduate degree in philosophy from Michigan State University and his graduate degree in philosophy from Oxford University, which he attended as a Rhodes Scholar.

Josh Mandel-Brehm

President & CEO, CAMP4 Therapeutics

Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics.

Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Michael Higgins

Chairman of Board, Voyager Therapeutics

Michael Higgins is a serial entrepreneur who has helped launch and build numerous companies during his 30+ year career. Michael served as Voyager Therapeutics Interim Chief Executive Officer, a role in which he was able to stabilize and relaunch the company through the completion of three major business development deals, restructuring of the management team and research portfolio, and recruitment of the long-term CEO. He gained venture experience as an Entrepreneur-in-Residence at Polaris Partners where he helped the founding team launch CAMP4 Therapeutics. Prior to his work at Polaris Partners, Mr. Higgins served for more than 10 years as Senior Vice President, Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals Inc., helping the company evolve from a venture backed start-up to a $2B fully integrated commercial organization. Prior to his time at Ironwood, Mr. Higgins held a variety of senior business positions at Genzyme Corporation.

In addition to his extensive biopharma management experience, Mr. Higgins has been a long-time Board member and Board Chair. He is currently Chairman of the Board of Voyager Therapeutics. Mr. Higgins also serves as chairman of the Board of Directors of Pulmatrix, Inc. (NASDAQ: PULM), and Nocion Therapeutics, Inc. (private). He also serves as a member of the Boards of Directors of Cyclerion Therapeutics, Inc. and Sea Pharmaceuticals. Mr. Higgins’ Board experience covers numerous therapeutic areas and involves work with nine first-time CEOs. Mr. Higgins has experience from seed stage financing to IPOs and beyond.

Mr. Higgins earned a B.S. from Cornell University and an MBA from the Amos Tuck School of Business at Dartmouth College.

Amir Nashat, ScD

Entrepreneur Partner, Polaris Partners

Amir Nashat is an entrepreneur partner in Polaris Partners’ Boston office and focuses on portfolio company executive roles as well as investing in healthcare companies. He joined Polaris in 2002 and also serves as a managing partner of Polaris Funds VI – IX.

Mr. Nashat is the CEO of Souffle Therapeutics and currently represents Polaris as a Director of CAMP4 Therapeutics, Dewpoint Therapeutics, and Paratus Sciences.

Additionally, Mr. Nashat has served as a director of Adnexus Therapeutics (acq Bristol Myers Squibb), Athenix Corporation (acq Bayer), Avila Therapeutics (acq Celgene), Fate Therapeutics (NASDAQ: FATE), Freenome, Living Proof (acq Unilever), Metacrine Therapeutics, Morphic Therapeutic (acq Lilly), Primmune Therapeutics, Promedior Pharmaceuticals (acq Roche), Receptos (acq Celgene), Scholar Rock (NASDAQ: SRRK), Selecta Biosciences (NASDAQ: SELB), Sun Catalytix (acq Lockheed Martin), Syros Pharmaceuticals (NASDAQ: SYRS), and TARIS Biomedical (acq J&J). He was also CEO of Polaris portfolio companies Dewpoint, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix.

Mr. Nashat serves on the Partners Innovation Fund and the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president.

He has been named to the Forbes Midas List of “Top 100 Venture Capitalists” (2016).
Prior to joining Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Mr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Andy Schwab

Managing Partner, 5AM Ventures

Andy Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of CAMP4 Therapeutics (NASDAQ: CAMP), DVS (acquired by Fluidigm), Enliven (NASDAQ: ELVN), Escient Pharmaceuticals (Incyte), Flexion Therapeutics (Pacira), Ikaria (Mallinckrodt), Ilypsa (Amgen), Precision NanoSystems (Danaher), Radionetics, RareCyte, Scientist.com (GHO Capital), Skye Bioscience (NASDAQ: SKYE), and TMRW. Mr. Schwab has also served on the Boards of Trustees of the California Academy of Sciences, Davidson College, and the National Venture Capital Association (NVCA). He received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team.

Murray Stewart, DM, FRCP

Senior Medical Advisor

Murray Stewart, DM, FRCP, is a Senior Medical Advisor to several companies and previously served as the corporate Chief Medical Officer at GlaxoSmithKline and subsequently as the Chief Medical Officer and head of R&D at Rhythm Pharmaceuticals and Novelion Therapeutics Inc.

Dr. Stewart has extensive clinical development experience in designing and completing studies through all stages of development from first-in-human trials to large Phase 4 cardiovascular outcome studies. He also provides guidance and strategy for early compounds in development in both small molecules and biologics as well as file submissions in the U.S., E.U. and other parts of the world, including Asia and Japan. Notable successful registrations and launches, including AVANDIA®, ARIXTRA®, TANZEUM®, and XOLREMDI®. Before joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and was Consultant Physician/Honorary Senior Lecturer and Head of Clinical Services at the Diabetes Centre, Newcastle upon Tyne in the UK. His research was in lipid metabolism in type-2 diabetes. He currently serve as a board director with X4 Pharmaceuticals.

Dr. Stewart completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.

Richard Young, PhD

Member, Whitehead Institute for Biomedical Research; Professor of Biology, Massachusetts Institute of Technology

Richard Young, PhD, studies gene regulatory circuitry in health and disease. His research accomplishments range from the development of genome-wide analysis technologies to discovery of the core regulatory circuitry of human embryonic stem cells. Dr. Young received his PhD in Molecular Biophysics and Biochemistry at Yale University, conducted postdoctoral research at Stanford University and joined Whitehead Institute and MIT in 1984. He has served as an advisor to the National Institutes of Health, the World Health Organization, the Vatican and numerous scientific societies and journals. Dr. Young has founded and advised numerous companies in the biotechnology and pharmaceutical industry. His honors include Membership in the National Academy of Sciences, the Chiron Corporation Biotechnology Research Award, Yale’s Wilbur Cross Medal, and in 2006 Scientific American recognized him as one of the top 50 leaders in science, technology and business.

Leonard Zon, MD

Harvard Medical School

Leonard Zon, MD, is the Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, and Director of the Stem Cell Program at Boston Children’s Hospital. Dr. Zon received his BS in chemistry and natural sciences from Muhlenberg College (1979) and his MD from Jefferson Medical College (1983). He subsequently did an internal medicine residency at New England Deaconess Hospital (1986) and a fellowship in medical oncology at Dana-Farber Cancer Institute (1989). His postdoctoral research was in Stuart Orkin’s laboratory (1990). Dr. Zon is internationally-recognized for his pioneering work in stem cell biology and cancer genetics. He has been the preeminent figure in establishing zebrafish as an invaluable genetic model for the study of the blood and hematopoietic development. He is founder and former president of the International Society for Stem Cell Research and chair of the Executive Committee of the Harvard Stem Cell Institute. In 2005, he completed a term as President of the American Society for Clinical Investigation. That same year, Dr. Zon was elected to the Institute of Medicine of the National Academies. In 2008, Dr. Zon was elected to the American Academy of Arts & Sciences. In 2010, Dr. Zon was awarded the E. Donnall Thomas Lecture and Prize from American Society of Hematology. In 2013, Dr. Zon received the ISEH Donald Metcalf Lecture Award. Other recent awards include the 2014 Boston Children’s Hospital Post-Doctoral Association Mentoring Award and the National Cancer Institute’s Alfred G. Knudson Award (2015). In 2022, Dr. Zon was elected to the National Academy of Sciences.

David Bumcrot, PhD

Scientific Fellow

David Bumcrot, PhD, is Scientific Fellow and former Chief Scientific Officer of CAMP4.

Prior to joining CAMP4, Dr. Bumcrot led groups at innovative biotech companies advancing novel technologies towards clinical development. He was one of the first employees at Alnylam pharmaceuticals where he spent ten years working to make RNA interference-based drugs a reality for multiple indications, including key contributions to a first-in-class systemically administered siRNA therapeutic tested in an oncology clinical trial. Dr. Bumcrot then moved on to Editas Medicine where his team established the company’s initial therapeutic programs utilizing groundbreaking CRISPR technology.

Dr. Bumcrot received his Bachelor of Science degree from Cornell University and a PhD in molecular biology from the University of Pennsylvania. He completed a post-doctoral fellowship at Harvard University.

Rachel Meyers, PhD

Scientific Fellow

Rachel Meyers, PhD, is a Scientific Fellow at CAMP4.

Dr. Meyers is an entrepreneurial scientist actively involved in the biotech and pharma industry. She is currently a member of the board of directors for Korro Bio, a nucleic acid therapeutics company focused on RNA editing as well as Atlas NewCo a stealth company in the nucleic acid therapeutic space. She also serves as a scientific advisor to Alnylam Pharmaceuticals, the pioneer of RNAi therapeutics and Arrakis Therapeutics, a small molecule company focused on targeting RNA. Rachel is a founding partner in Sunrise Bioventures, a nucleic acid accelerator, and serves as acting CEO at AmyGo Solutions, a startup focused on early detection in amyloidosis. In addition to other advisory roles across the industry, Dr. Meyers serves as mentor with several local and national biotech entrepreneurial programs including serving on the National Advisory Council on Innovation and Entrepreneurship (NACIE) during the Biden administration.

Dr. Meyers has more than 25 years of drug discovery and development expertise as well as extensive experience in building R&D organizations. Previously she served as Founder and Chief Scientific Officer at Faze Medicines, a Third Rock Ventures-backed biotech company focused on treating diseases through the perturbation of biomolecular condensates. She has deep expertise in the development of RNA-based therapies having spent 14 years at Alnylam Pharmaceuticals, helping to build the company from the beginning, ultimately serving as the SVP of Research and RNAi Lead Development. Prior to Alnylam, Dr. Meyers was a senior scientist at Millennium Pharmaceuticals.

Dr. Meyers completed her postdoctoral training with Lew Cantley at Harvard Medical School in the field of signal transduction and received her PhD from Nobel laureate Phil Sharp at MIT in the field of in vitro transcription.